Skip to content
OpenCapital
Get started

Aurinia Pharmaceuticals AUPH Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
——
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
——

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Aurinia Pharmaceuticals (AUPH) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $10.55 in Q1 2026.
How has Aurinia Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
Aurinia Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price increased by 1.5% year-over-year, from $10.39 to $10.55.
What is the long-term trend for Aurinia Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a -6.1% compound annual growth rate (CAGR), from $12.84 to $9.98.